+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Castration-resistant Prostate Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Castration-resistant Prostate Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Castration-resistant Prostate Cancer Drugs Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6161039
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Castration-Resistant Prostate Cancer Drugs: Executive Overview

Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite androgen-deprivation therapy (ADT), often reflected by rising prostate-specific antigen (PSA), radiographic progression, or clinical deterioration. Treatment decisions are increasingly guided by disease setting, prior therapies, symptoms, metastatic status, comorbidities, genomic findings, and patient preferences. The therapeutic landscape includes androgen-receptor pathway inhibitors, taxane chemotherapy, radiopharmaceuticals, bone-directed treatments, and selected biomarker-directed options. Care is shifting toward earlier risk assessment, multidisciplinary coordination, and sequencing strategies that preserve quality of life while addressing resistance mechanisms.

Treatment Is Shifting Toward Earlier Stratification and Combination-Aware Care

CRPC management is being reshaped by earlier identification of high-risk disease, broader use of molecular testing, and greater attention to treatment sequencing. Clinicians increasingly distinguish nonmetastatic from metastatic CRPC and further classify metastatic disease by symptoms, visceral involvement, prior exposure, and pace of progression. Resistance after androgen-receptor pathway inhibition has reinforced the need to avoid ineffective sequential use of therapies with overlapping mechanisms, while radioligand and biomarker-directed approaches have expanded options for appropriately selected patients. Supportive care, treatment adherence, cardiovascular monitoring, fall prevention, and management of skeletal complications are becoming integral parts of therapeutic planning rather than separate considerations.

Artificial Intelligence Is Strengthening Diagnosis, Trial Design, and Treatment Selection

Artificial intelligence can support CRPC care by extracting progression signals from imaging, PSA trajectories, pathology, electronic records, and genomic data. Machine-learning tools may help identify radiographic progression earlier, characterize heterogeneous lesions, predict treatment response, and prioritize patients for clinical trials. AI-assisted trial matching and real-world evidence analysis can also clarify outcomes across treatment sequences and underrepresented populations. However, clinical usefulness depends on validated datasets, transparent performance measures, external testing, cybersecurity, and clinician oversight. Bias in imaging, genomic, and health-record data remains a material risk, so AI should augment-not replace-multidisciplinary judgment and shared decision-making.

Regional Insights: Uneven Access and Distinct Evidence-to-Practice Priorities

North America generally emphasizes rapid adoption of novel systemic therapies, biomarker testing, radioligand infrastructure, and real-world comparative evidence, although affordability and insurance coverage remain important constraints. Europe combines guideline-driven care with strong health-technology assessment, producing variation in reimbursement and access across countries. Asia-Pacific includes sophisticated oncology systems alongside substantial differences in diagnostic capacity, clinical-trial participation, and access to advanced imaging and radiopharmaceutical services. Latin America faces uneven availability of specialized oncology care, molecular testing, and high-cost treatments, making referral networks and budget-sensitive pathways important. The Middle East is expanding oncology infrastructure, with access varying by national program, private-sector capacity, and specialist concentration. Africa continues to face major challenges involving late diagnosis, limited oncology workforce capacity, pathology access, radiotherapy availability, and continuity of treatment, highlighting the importance of scalable diagnostics and supportive-care systems.

Group Insights: Policy Alignment and Infrastructure Shape Adoption

ASEAN economies show varied oncology maturity, with regional cooperation, referral pathways, and harmonized evidence requirements potentially improving access to specialist care. BRICS countries combine large and diverse patient populations with different regulatory, manufacturing, reimbursement, and clinical-trial environments; local evidence generation and supply resilience are recurring priorities. The European Union benefits from shared scientific and regulatory frameworks, while national reimbursement decisions continue to determine practical availability. G7 health systems tend to have strong research and specialist capabilities but remain focused on affordability, value assessment, workforce pressures, and equitable access. GCC countries are investing in advanced healthcare infrastructure and centralized specialist services, while workforce development and cross-border coordination remain relevant. NATO members have diverse health systems, but many share priorities involving resilient pharmaceutical supply chains, oncology preparedness, and secure health-data infrastructure.

Country Insights: Different Health-System Conditions Require Localized Execution

Australia combines specialist oncology expertise with geographic access challenges, making tele-oncology and coordinated referral important. Brazil and Mexico must address regional disparities in specialist care, diagnostics, and public-sector access. Canada and the United States have strong research and treatment capabilities, but coverage, affordability, and geographic variation influence utilization. China is expanding oncology capacity and domestic innovation while continuing to manage regional variation and evidence requirements. India faces substantial differences between metropolitan and rural care, with affordability, pathology, and specialist capacity central to access. Japan, South Korea, Singapore, and other advanced Asian systems emphasize guideline-based care, aging-population needs, and infrastructure for precision oncology. France, Germany, Italy, Spain, and the United Kingdom pair established cancer services with national or regional reimbursement processes, workforce constraints, and differing approaches to health-technology assessment. Russia faces challenges involving access continuity, specialist distribution, and supply-chain reliability.

Action Priorities for Leaders: Build Evidence, Access, and Care Coordination Together

Industry leaders should organize development and commercialization around clinically meaningful patient segments rather than treatment labels alone. Priority actions include investing in prospective biomarker strategies, head-to-head or pragmatic sequencing evidence, and outcomes that capture survival, symptoms, functional status, and quality of life. Organizations should strengthen companion-diagnostic partnerships, radiopharmaceutical and imaging capacity, pharmacovigilance, and patient-support services while designing access programs that reflect public and private reimbursement realities. Regional launch plans should account for pathology standards, referral patterns, workforce limitations, and supply-chain requirements. AI initiatives should use clinically validated datasets, explainable workflows, prospective monitoring, and clear accountability. Collaboration with clinicians, patients, payers, regulators, and advocacy groups can improve adoption while reducing avoidable disparities.

Research Methodology: Evidence-Based Synthesis of CRPC Treatment Dynamics

This executive summary uses a structured qualitative synthesis of established CRPC clinical concepts, treatment modalities, care pathways, health-system differences, and technology trends. The analysis distinguishes nonmetastatic and metastatic disease, considers prior ADT and systemic exposure, and incorporates diagnostic, therapeutic, supportive-care, regulatory, reimbursement, and infrastructure factors. Regional, group, and country observations are framed as health-system and access considerations rather than quantitative market claims. No market estimates, market shares, forecasts, or company-specific assessments are used. Interpretation should be updated against current clinical guidelines, regulatory decisions, peer-reviewed evidence, and locally applicable reimbursement policies.

Conclusion: Better Stratification and Equitable Delivery Will Define Progress

CRPC care is becoming more personalized, evidence-intensive, and dependent on coordinated delivery across diagnostics, systemic treatment, radiopharmaceutical services, supportive care, and survivorship planning. The central opportunity is to match the right therapy and sequence to disease biology, prior exposure, patient goals, and health-system capacity. Progress will depend not only on therapeutic innovation but also on validated biomarkers, robust comparative evidence, reliable supply, trained multidisciplinary teams, and equitable access to testing and treatment. Leaders that combine clinical precision with implementation discipline will be best positioned to improve outcomes across diverse populations and regions.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Castration-resistant Prostate Cancer Drugs Market, by Androgen Receptor Axis Targeted Agents
7.1. Introduction
7.2. Abiraterone
7.3. Apalutamide
7.4. Darolutamide
7.5. Enzalutamide
7.6. Pipeline Agents
7.6.1. Proxalutamide
7.6.2. Rezvilutamide
8. Castration-resistant Prostate Cancer Drugs Market, by Chemotherapy Agents
8.1. Introduction
8.2. Cabazitaxel
8.3. Docetaxel
9. Castration-resistant Prostate Cancer Drugs Market, by Radiopharmaceuticals
9.1. Introduction
9.2. Lutetium 177 Psma
9.3. Radium 223
10. Castration-resistant Prostate Cancer Drugs Market, by Immunotherapy
10.1. Introduction
10.2. Pembrolizumab
10.3. Sipuleucel T
11. Castration-resistant Prostate Cancer Drugs Market, by Bone Targeted Therapy
11.1. Introduction
11.2. Denosumab
11.3. Zoledronic Acid
12. Castration-resistant Prostate Cancer Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Castration-resistant Prostate Cancer Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Castration-resistant Prostate Cancer Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Astellas Pharma Inc.
16.2. AstraZeneca PLC
16.3. Bayer AG
16.4. Clovis Oncology, Inc.
16.5. Dendreon Pharmaceuticals LLC
16.6. Exelixis, Inc.
16.7. Janssen Biotech, Inc.
16.8. Johnson & Johnson
16.9. Myovant Sciences Ltd.
16.10. Pfizer Inc.
16.11. Sanofi S.A.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Castration-resistant Prostate Cancer Drugs Market, Years Considered for the Study
FIGURE 2. Global Castration-resistant Prostate Cancer Drugs Market, Research Design
FIGURE 3. Global Castration-resistant Prostate Cancer Drugs Market, Research Framework
FIGURE 4. Global Castration-resistant Prostate Cancer Drugs Market, Data Triangulation
FIGURE 5. Global Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2025 vs 2032 (%)
FIGURE 7. Global Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2025 vs 2032 (%)
FIGURE 9. Global Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2025 vs 2032 (%)
FIGURE 11. Global Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2025 vs 2032 (%)
FIGURE 13. Global Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2025 vs 2032 (%)
FIGURE 15. Global Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Castration-resistant Prostate Cancer Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Castration-resistant Prostate Cancer Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Castration-resistant Prostate Cancer Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Castration-resistant Prostate Cancer Drugs Market Segmentation & Coverage
TABLE 2. Global Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 4. Global Abiraterone Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Abiraterone Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Abiraterone Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Apalutamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Apalutamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Apalutamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Darolutamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Darolutamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Darolutamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Enzalutamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Enzalutamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Enzalutamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Pipeline Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Pipeline Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Pipeline Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Proxalutamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Proxalutamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Proxalutamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Rezvilutamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Rezvilutamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Rezvilutamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 26. Global Cabazitaxel Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Cabazitaxel Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Cabazitaxel Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Docetaxel Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Docetaxel Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Docetaxel Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 33. Global Lutetium 177 Psma Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Lutetium 177 Psma Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Lutetium 177 Psma Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Radium 223 Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Radium 223 Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Radium 223 Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 40. Global Pembrolizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Pembrolizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Pembrolizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Sipuleucel T Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Sipuleucel T Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Sipuleucel T Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 47. Global Denosumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Denosumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Denosumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Zoledronic Acid Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Zoledronic Acid Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Zoledronic Acid Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 61. North America Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 63. North America Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 64. North America Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 65. North America Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 66. North America Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 67. North America Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 68. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 70. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 71. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 72. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 73. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 74. Latin America Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 75. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 77. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 78. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 79. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 80. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 81. Europe Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 82. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 84. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 85. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 86. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 87. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 88. Middle East Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 89. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 91. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 92. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 93. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 94. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 95. Africa Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 96. Global Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 99. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 100. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 101. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 102. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 103. ASEAN Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 104. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 106. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 107. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 108. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 109. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 110. GCC Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 111. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 113. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 114. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 115. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 116. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 117. European Union Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 118. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 120. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 121. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 122. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 123. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 124. BRICS Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 125. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 127. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 128. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 129. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 130. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 131. G7 Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 132. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 134. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 135. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 136. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 137. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 138. NATO Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 139. Global Castration-resistant Prostate Cancer Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. United States Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 141. United States Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 142. United States Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 143. United States Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 144. United States Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 145. United States Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 146. United States Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 147. Canada Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 148. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 149. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 150. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 151. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 152. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 153. Canada Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 154. Mexico Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 155. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 156. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 157. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 158. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 159. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 160. Mexico Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 161. Brazil Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 163. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 164. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 165. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 166. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 167. Brazil Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 168. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 170. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 171. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 172. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 173. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 174. United Kingdom Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 175. Germany Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 176. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 177. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 178. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 179. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 180. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 181. Germany Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 182. France Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 183. France Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 184. France Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 185. France Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 186. France Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 187. France Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 188. France Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 189. Russia Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 191. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 192. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 193. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 194. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 195. Russia Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 196. Italy Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 198. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 199. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 200. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 201. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 202. Italy Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 203. Spain Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 205. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 206. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 207. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 208. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 209. Spain Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 210. China Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 211. China Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 212. China Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 213. China Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 214. China Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 215. China Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 216. China Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 217. India Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 218. India Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 219. India Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 220. India Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 221. India Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 222. India Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 223. India Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 224. Japan Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 225. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 226. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 227. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 228. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 229. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 230. Japan Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 231. Australia Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 232. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 233. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 234. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 235. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 236. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 237. Australia Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 238. South Korea Castration-resistant Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
TABLE 239. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Androgen Receptor Axis Targeted Agents, 2017-2032 (USD Million)
TABLE 240. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Pipeline Agents, 2017-2032 (USD Million)
TABLE 241. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Chemotherapy Agents, 2017-2032 (USD Million)
TABLE 242. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Radiopharmaceuticals, 2017-2032 (USD Million)
TABLE 243. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 244. South Korea Castration-resistant Prostate Cancer Drugs Market Size, by Bone Targeted Therapy, 2017-2032 (USD Million)
TABLE 245. Global Castration-resistant Prostate Cancer Drugs Market Share, by Key Player, 2025
TABLE 246. Global Castration-resistant Prostate Cancer Drugs Market, Key Experts

Companies Mentioned

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals LLC
  • Exelixis, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Myovant Sciences Ltd.
  • Pfizer Inc.
  • Sanofi S.A.

Related Topics

Related Reports

Castration-Resistant Prostate Cancer (CRPC) or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026 - Product Image

Castration-Resistant Prostate Cancer (CRPC) or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Castration-sensitive Prostate Cancer - Market Insights, Epidemiology, and Market Forecast - 2036 - Product Image

Castration-sensitive Prostate Cancer - Market Insights, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035 - Product Image

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035

  • Report
  • 90 Pages
  • Global
From
Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 432 Pages
  • Global
From
Enzalutamide Drugs Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Drugs Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.